Abstract
Introduction
Approximately 15% to 20% of invasive breast cancers have amplification of the human epidermal growth factor receptor 2 (HER2) genes or overexpression of the HER2 protein.
Before the availability of HER2-directed therapies, women with early-stage HER2-positive breast cancer faced a worse prognosis than those with a diagnosis of HER2-negative disease, with shorter time to disease relapse, an increased incidence of metastases, and higher mortality. 1
Trastuzumab, a humanized monoclonal antibody that targets the extracellular domain of the HER2 protein, was found to improve survival in the metastatic disease setting when used in combination with chemotherapy. 2 Breast cancer is the most common cancer in women worldwide 4 . It is also the principle cause of death from cancer among women globally. Despite the high incidence rates, in Western countries, 89% of women diagnosed with breast cancer are still alive 5 years after their diagnosis, which is due to proper detection and treatment. Taxotere (75mg/m 2 ) as 1 hour infusion preceded by doxorubicin (50mg/m 2 ) and Herceptin (8mg/kg) for 1st cycle and 6mg/kg onwards for 12 cycle in every 3 weeks.
(Placebo) n=17
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Results and Discussion
Breast cancer is the most common cancer in women worldwide 4 . It is also the principle cause of death from cancer among women globally. Despite the high incidence rates, in Western countries, 89% of women diagnosed with breast cancer are still alive 5 years after their diagnosis, which is due to proper detection and treatment. Mainly there are several types of breast cancer. One of the classes is determined by the expression of proteins or receptor and genes 10, 11, 12 . Cells have receptors on their surface and in their cytoplasm and nucleus. Chemical messengers such as hormones bind to receptors, and this causes changes in the cell. Breast cancer cells may or may not have many different types of receptors, the three most important in the present classification being: estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. Cells with or without these receptors are called ER positive (ER+), ER negative (ER-), PR positive (PR+), PR negative (PR-), HER2 positive (HER2+), and HER2 negative (HER2-). Cells with none of these receptors are called basal-like or triple negative. HER2/neu (human epidermal growth factor receptor 2), also called ErbB2, is a protein that appears on the surface of some breast cancer cells. This protein is an important part of the pathway for cell growth and survival. It may also stimulate the immune system to more effectively attack the cancer.
10, 11
Inclusion Criteria Eligible patients were 25 to 70 years of age. All were female patients with Her2 positive stage II and Stage III invasive duct cell carcinoma. The patients were treated with the cytotoxic chemotherapy with or without Trastuzumab at different private hospitals and clinics in Rajshahi city during January 2013 to December 2015. The study was followed by all the code and ethics. All the patients were aware about the study. We have divided our study population in three age groups (25-35 years, 36-50 years and above 50 years. Most of the patients belong to the Middle class family. Because the socio economic condition of the patients who came from Rajshahi, Naogaon, Natore and Chapainawabganj was good. Among 130 patients 68 patients were belong to middle class group. 45 patients belong to upper middle class and 17 patients were from lower middle class. Among 130 patients 79 patients had family history of breast cancer or any other cancers that is 61%. 51 patients (39%) did not have any family history of breast cancer before.
Age
According to breast feeding vs incidences, among 130 patients only 23 patients used to breastfeed their children and remaining 107 patients did not.
Fig 2: Breast Feeding vs Incidence
A satisfactory explanation for the excess incidence of left breast cancers has not yet been elucidated. However, it has been well established that, on average, the left breast is slightly larger than the right. The finding of increased overall incidence of left breast cancer also extended to males. Data from a pooled analysis of 18 US studies was reported in 1959 and showed a four percent excess in left breast cancers.
• This lends itself to the logic that more breast tissue is present to be at risk for the development of a cancer.
• Left sided disease was more common only after reaching the age of 45.
• For women younger than 45, right handedness, never having been pregnant and late age for beginning to have menstrual periods was associated with a higher incidence of right breast cancer.
14, 15,16 In the comparison the major outcome between TAC and TAH about the overall survival (OS), the evidence of this study is using TAH will provide (28.511-23.33) = 5.181 months probability of more survival over TAC. The addition of trastuzumab to docetaxel after doxorubicin and cyclophosphamide in early-stage HER2-positive breast cancer results in a substantial and durable improvement in survival as a result of a sustained marked reduction in cancer recurrence.
Conclusion
Trastuzumab + Cytotoxic Chemotherapy significantly improves OS vs Cytotoxic Chemotherapy alone.30% risk reduction of death (HR=0.70, P =.011) 28.51 months median OS vs 23.33 months with Cytotoxic Chemotherapy alone. OS benefit was consistent across subgroups. The major outcome between TAC and TAH about the overall survival, TAH will provide (28.511-23.33) = 5.181 months probability of more survival over TAC. Trastuzumab significantly improves quality of life.
